Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1360-0443.2008.02352.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Wider availability of cannabis through medical and recreational legalization (MCL alone and RCL+MCL) has been hypothesized to contribute to reductions in opioid use, misuse, and related harms. We examined whether state adoption of cannabis laws was associated with changes in opioid outcomes overall and stratified by cannabis use.
Methods: Using National Survey on Drug Use and Health (NSDUH) data from 2015 to 2019, we estimated cannabis law associations with opioid (prescription opioid misuse and/or heroin use) misuse and use disorder.
Substance use and psychiatric outcomes following substance use disorder treatment: An 18-month prospective cohort study in Chile.
Addiction
January 2025
Center for Studies on Justice and Society (CJS), Pontificia Universidad Católica de, Chile.
Background And Aims: Evidence from high-income countries has linked duration and compliance with treatment for substance use disorders (SUDs) with reductions in substance use and improvements in mental health. Generalizing these findings to other regions like South America, where opioid and injection drug use is uncommon, is not straightforward. We examined if length of time in treatment and compliance with treatment reduced subsequent substance use and presence of psychiatric comorbidities.
View Article and Find Full Text PDFDried Cannabis Use, Tobacco Smoking, and COVID-19 Infection: Findings from a Longitudinal Observational Cohort Study.
Cannabis
December 2024
Firestone Institute for Respiratory Health - Division of Respirology, Department of Medicine, McMaster University.
Objective: The potential impact of cigarette and cannabis smoking on COVID-19 infection outcomes is not well understood. We investigated the association between combustible tobacco use and dried cannabis use with COVID-19 infection in a longitudinal cohort of community adults.
Method: The sample comprised 1,343 participants, originally enrolled in 2018, who reported their cigarette and cannabis use in 11 assessments over 44 months, until 2022.
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.
EClinicalMedicine
August 2024
Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, United Kingdom.
Background: While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric events have emerged. More data are therefore needed to assess the effects of semaglutide on brain health. This study provides robust estimates of the risk of neurological and psychiatric outcomes following semaglutide use compared to three other antidiabetic medications.
View Article and Find Full Text PDFEvaluation of the Association Between Prenatal Cannabis Use and Risk of Developmental Delay.
JAACAP Open
December 2024
University of British Columbia, Vancouver, British Columbia, Canada.
Objective: Conflicting results have arisen regarding the association between prenatal cannabis exposure and risk of parent-reported developmental delay in infancy. In certain instances, this literature has become outdated or failed to adjust for confounding variables. The current study aimed to determine if prenatal cannabis exposure was associated with a greater likelihood of risk of parent-reported developmental delay at 12 months of age in a contemporary cohort, while adjusting for common confounding variables.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!